Last updated: April 25, 2025
Sponsor: Thammasat University
Overall Status: Active - Recruiting
Phase
4
Condition
Emphysema
Lung Disease
Chronic Obstructive Lung Disease
Treatment
Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)
Budesonide/Glycopyrronium/Formoterol (BGF)
Clinical Study ID
NCT06905483
MTU-EC-IM-5-271/67
Ages 40-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
COPD diagnosis confirmed by spirometry (post-bronchodilator FEV1/FVC < 70%)
Aged 40-80 years
Smoking 10 pack-years or more
Postbronchodilator FEV1 < 80%
Exclusion
Exclusion Criteria:
History of COPD exacerbation within 3 months
Asthma, bronchiectasis, pulmonary fibrosis
Inability to perform spirometry, impulse oscillometry, or 6-minute walk test
Pregnant or breastfeeding women
Study Design
Total Participants: 28
Treatment Group(s): 2
Primary Treatment: Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)
Phase: 4
Study Start date:
April 01, 2025
Estimated Completion Date:
March 31, 2026
Study Description
Connect with a study center
Narongkorn Saiphoklang
Pathumthani, 12120
ThailandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.